| 产品描述: | Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC). Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. |
| 靶点: |
MMP |
| 体外研究: |
Apratastat (10 mg/kg, 腹腔注射,给药两次,分别在诱导后的 4 小时和 16 小时) 减轻了由 Poly(I) 和 SARS-CoV-2 RBD-S 蛋白诱导的 C57BL/6 小鼠肺部炎症[3]。 Apratastat (10 mg/kg,口服,每日一次,共 14 天) 在 MC38 异种移植 C57BL/6 小鼠模型中表现出抗肿瘤和抗血管生成活性[4]。 |
| 体内研究: |
Apratastat (10 μM, 24 小时) 在肺组织样本中抑制促炎性细胞因子 TNF-α 和 IL-6 的表达 。
Apratastat (10 μM, 24 小时) 在 HUVEC 细胞中降低 ADAM17 活性并减少 MCAM 的释放 。 |
| 参考文献: |
1. Shu C, et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J Clin Pharmacol. 2011 Apr;51(4):472-81. 2. Ieguchi K, et al. Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer. J Thorac Dis. 2016 Aug;8(8):E813-5. 3. Lartey NL, et al. ADAM17/MMP inhibition prevents neutrophilia and lung injury in a mouse model of COVID-19. J Leukoc Biol. 2022 Jun;111(6):1147-1158. 4. Stalin J, et al. Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer. Biomedicines. 2023 Nov 30;11(12):3185. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.413 ml |
12.063 ml |
24.125 ml |
| 5 mM |
0.483 ml |
2.413 ml |
4.825 ml |
| 10 mM |
0.241 ml |
1.206 ml |
2.413 ml |
| 50 mM |
0.048 ml |
0.241 ml |
0.483 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |